Physician profile

Adam Michael Close

Obstetrics & Gynecology · Palm Bay, FL

NPI 1649681602

$3,925.16

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$286.36

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $3,006.23 2022
Abbvie INC. $476.25 2019-2023 Liletta
Mayne Pharma Commercial LLC $214.93 2023
Hologic Sales and Service, LLC $115.76 2019-2023 Omni Hysteroscope
Merck Sharp & Dohme LLC $35.96 2019-2020
Bayer Healthcare Pharmaceuticals INC. $28.80 2019-2020
Therapeuticsmd, INC. $20.76 2019
Pfizer INC. $18.36 2021
Meditrina $8.11 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adam Michael Close

$3,925.16

in general payments reported 2019-2025

Years
2019-2023
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/5338944/adam-michael-close

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.